|
|
|
| home > white papers > The Use of Stainless Steel Equipment Within Laboratories and Clean Rooms - Teknomek Ltd |
|
|
 WHITE PAPERS |
|
Teknomek Ltd
|
|
The Use of Stainless Steel Equipment Within Laboratories and Clean Rooms
|
|
Teknomek explains why stainless steel is the material of choice for laboratories and hygienic manufacturing.
Clean and safe environments are essential criteria for compliance with UK Medicines and Healthcare products Regulatory Agency (MHRA) regulations. To support this, furniture and equipment must facilitate Good Manufacturing Practice (GMP) by withstanding thorough cleaning and maintenance.
Stainless steel furniture and equipment helps businesses to meet the stringent hygiene audits set by the MHRA. The material is incredibly versatile when it comes to design, plus is robust enough to withstand the most rigorous of cleaning processes. It is common practice for stainless steel furniture providers to work very closely with their customers to deliver tailor-made solutions that comply with regulatory criteria...
Download this white paper to find out more.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
SHIONOGI’S NOVEL ANTIBIOTIC, FETCROJA® (CEFIDEROCOL), HAS BEEN SELECTED BY UK’S NICE / NHSE&I AS PART OF AN ANTIMICROBIAL SUBSCRIPTION STYLE REIMBURSEMENT MODEL
The National Institute for Clinical and Health Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) have recognised the potential of Shionogi’s innovative antibiotic, cefiderocol, and selected it for inclusion in this pilot reimbursement model which ‘de-links’ payment from volume of use
Shionogi recognises the UK’s leadership role in introducing this first fully ‘delinked’ pilot reimbursement model, which is an important step in making the market for novel antibiotics more predictable and sustainable; we strongly believe in the introduction of further suitable pull incentives in order to help stimulate the antimicrobial development pipeline
Fetcroja® (cefiderocol) is indicated for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options1
Antimicrobial resistance (AMR) is a major health burden which results in over 700,000 deaths globally2 and 5,000 deaths per year in the UK3 from an infection with multidrug-resistant bacteria and this is predicted to kill 10 million people every year globally by 2050, unless action is taken2
More info >> |
|
 |
White Papers |
 |
|
Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.
Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >> |
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
|
|
